ÂÜÀòÂÒÂ×

Dr. Raj Manchanda joins APIE Therapeutics as Chief Technical Officer Advisor to lead and further advance the CMC & supply chain aspects for the transition of Idiopathic Pulmonary Fibrosis (IPF)and Heart Failure (HF)therapies from pre-clinical trials into clinical trials. Dr. Manchanda is the Chief Technical Operations Officer at Anokion and leads all aspects of the company’s CMC, quality control, and drug supply activities. Raj brings over 23 years of pharmaceutics development and program management experience to Anokion and most recently was Innovation Portfolio Leader at the Bill & Melinda Gates Medical Research Institute.

Previously, he was Chief Development Officer at Frequency Therapeutics, where he had oversight of drug development and manufacturing, portfolio and project management, infrastructure-building, and execution of global clinical development and regulatory strategy. Prior to Frequency, Raj was Vice President of Neurodegeneration and Early-Stage Therapeutics Asset Development at Biogen. While at Biogen, he was instrumental in leading the CMC development for approval and commercialization for Tecfideraâ„¢.

During his 23 years in the pharmaceutical industry, he has worked on over 25 INDs and 6 NDAs, including two drug development programs that received Fast Track designation from the U.S. Food and Drug Administration. Raj received his Ph.D. in Chemistry from Yale University and was an Anna Fuller postdoctoral fellow at MIT. Raj has also completed the Advanced Management Program from the Sloan School of Management at MIT.